Zevra Therapeutics, Inc. Impairment of Intangible Assets (Excluding Goodwill)
Zevra Therapeutics, Inc. (ZVRA) reported Impairment of Intangible Assets (Excluding Goodwill) of $0 for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill · last filed 2026-08-05
- Zevra Therapeutics, Inc. impairment of intangible assets (excluding goodwill) for the quarter ending 2026-06-30 was $0.00, a 100.00% decline year-over-year.
- Zevra Therapeutics, Inc. impairment of intangible assets (excluding goodwill) for the quarter ending 2025-06-30 was $58.71M.
| Period end | Impairment of Intangible Assets (Excluding Goodwill) 3 month | Impairment of Intangible Assets (Excluding Goodwill) 6 month |
|---|---|---|
| 2026-06-30 | $0.00 10-Q · filed 2026-08-05 | $0.00 10-Q · filed 2026-08-05 |
| 2025-06-30 | $58.71M 10-Q · filed 2026-08-05 | $58.71M 10-Q · filed 2026-08-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |